Craft
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
banner
Mirati Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, cash flow, and acquistions and subsidiaries.

Revenue

$12.4 M

FY, 2022

CreditSafe Score

?
Score changed on Feb 13, 2025
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn more

Financial Statements

USDFY, 2020FY, 2021FY, 2022
Revenue13.4M72.1M12.4M
Cost of goods sold600.0K
Gross profit11.8M
Gross profit margin, %95.2%
General and administrative expense83.4M136.7M239.8M
Operating expense total382.8M645.3M771.4M
EBIT(369.4M)(573.2M)(759.6M)
EBIT margin, %-2756.9%-795.1%-6108.0%
Pre tax profit(357.9M)(578.5M)(740.4M)
Income tax expense3.3M508.0K
Net Income(357.9M)(581.8M)(740.9M)
EPS(8.0)(11.2)(13.2)

Acquisitions & Subsidiaries

Company nameDateDeal size
LoremDec 23, 2021$40.0M
IpsumJan 18, 2022$30.0M
Lorem IpsumFeb 18, 2022$25.0M
DolorOct 21, 2021$60.0M
Premium Content only available in Craft’s Intelligence Portal
View acquisitions and subsidiaries by company, date, and deal size.
Understanding this data enables better supplier & customer negotiations and helps identify potential opportunities or market risks for your firm.
Learn more

Footer menu